Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now
10:00am, Saturday, 17'th Feb 2024
Surgical robotics and the rare disease drug market are two rapidly growing areas of healthcare. Intuitive Surgical makes most of its money from recurring revenue, a business model that has held up.
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.
07:15am, Thursday, 15'th Feb 2024
Vertex Pharmaceuticals is in the middle of an extremely formative period for its business. Netflix is seeing a windfall of growth from its ad-supported tier, and profits are flowing.
Gene therapy: Why does it cost millions for a single treatment?
07:01am, Thursday, 15'th Feb 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medic
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
05:50am, Thursday, 15'th Feb 2024
Vertex's P/S ratio is very high, relative to most other biopharma stocks. It's important, though, to look to the future rather than the past when considering the company's valuation.
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
08:36am, Wednesday, 14'th Feb 2024
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for tre
Stock-Split Watch: Is Vertex Pharmaceuticals Next?
05:05am, Wednesday, 14'th Feb 2024
Vertex Pharmaceuticals' shares have climbed nearly 80% in two years. Its share price recently reached an all-time high, and key catalysts ahead could push it higher.
2 Healthcare Stocks That Could Help Set You Up for Life
09:45am, Monday, 12'th Feb 2024
Healthcare spending represents a tremendous, multitrillion-dollar market opportunity. Vertex just earned another product approval, and more growth could be just over the horizon.
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
06:51am, Sunday, 11'th Feb 2024
The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.
Cooling Off? 3 Popular Stocks With Recent Target Cuts
06:13am, Sunday, 11'th Feb 2024
While many S&P 500 stocks are reaching recent highs, Wall Street analysts are also reassessing their price targets and issuing outlook changes and downgrades for a number of companies. Today, we intro
Is Vertex Pharmaceuticals Stock a Buy Now?
12:37pm, Saturday, 10'th Feb 2024
Drugmaker and cystic fibrosis specialist Vertex expects modest growth for 2024. The company has promising products in its pipeline, but they could still be years away.
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
09:45am, Saturday, 10'th Feb 2024
The rare disease drug market and telehealth market are two expanding areas of healthcare. CF specialist Vertex had another great year in 2023, and the long-term horizon looks even rosier.
2 No-Brainer Healthcare Stocks to Buy Right Now
08:30am, Saturday, 10'th Feb 2024
Its essential nature helps the healthcare industry generate more consistent consumer spending. DexCom is raking in profits from its latest product, and it's still looking at a vast long-term opportuni
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
06:25am, Friday, 09'th Feb 2024
Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can g
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
11:31am, Tuesday, 06'th Feb 2024
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
This High-Flying Stock Just Got Some Bad News: Should You Sell?
05:15am, Tuesday, 06'th Feb 2024
Vertex Pharmaceuticals' acute pain candidate was not as impressive as hoped in a late-stage study. Still, the drugmaker has an excellent lineup and multiple highly promising pipeline candidates.
